Marker Therapeutics, Inc.

Monthly Archives: May 2017

TapImmune Provides First Quarter 2017 Corporate and Clinical Update Today

TapImmune is hosting a conference call and live audio webcast today, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.
Read More

TapImmune Completes Successful Multi-Gram Scale-Up of TPIV 200

TapImmune Inc. has completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, which is a multi-epitope T-cell vaccine developed by the company that targets the folate receptor alpha
Read More

TapImmune to Provide First Quarter 2017 Business Update Conference Call and Webcast

TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.
Read More

Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

Targeting the immune system to fight cancer is not new: in 1891, New York bone sarcoma surgeon William B. Coley injected a patient with an inoperable malignant tumor with streptococcal organisms. His theory was that the resulting severe bacterial infection, erysipelas, would stimulate the immune system, shrinking the tumor.
Read More

Q&A with new Medical Director of TapImmune (TPIV), Dr. Richard Kenney

On May 1st, TapImmune announced Richard Kenney, MD, FACP, was joining TapImmune to lead the Clinical Development Program. Dr. Kenney will manage TapImmune’s ongoing and planned clinical programs for its next-generation T-cell vaccine candidates, which currently include multiple Phase 2 trials in advanced breast and ovarian cancer.
Read More

U.S. Department of Defense Fully Funds Phase II Breast Cancer Study

TapImmune is advancing two Phase II studies that are funded by ~$17 million in non-dilutive grants from the U.S. Department of Defense.
Read More

Richard Kenney, MD, FACP, Joins TapImmune to Lead the Clinical Development Program

TapImmune announced that on May 1, 2017, Dr. Richard Kenney will manage TapImmune’s ongoing and planned clinical programs for its next-generation T-cell vaccine candidates, which currently include multiple Phase 2 trials in advanced breast and ovarian cancer.
Read More